Loading stock…

Adaptive Biotechnologies Corporation (ADPT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Adaptive Biotechnologies Corporation

ADPTMarket cap $4.19BPrice $26.3

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Maps the immune system's response to diseases using its TCR sequencing platform, decoding billions of T-cell receptors to diagnose cancer and infections early. Its MRD test spots leftover cancer cells regular scans completely miss.

In Bastion Portfolios?

52W Return+61%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+14%8

Revenue Forecast

Rev CAGR (1y)+6%5

Rev CAGR (3y)+17%9

Rev CAGR (5y)+20%9

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-12%1

Net Income Margin-21%1

Free Cash Flow Margin-8%2

Debt

Net Debt/EBITDAna–

Efficiency

ROE-40%1

ROA-11%1

Earnings Stabilityna–

GEAR+VERY WEAK9

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV29.31

EV Multiples

EV/EBITDA Fwd1,2151

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-0.6%2

Dividend Yieldna–

Momentum

Short term

1 month return+8%10

3 month return+30%10

YTD return+62%10

Mid term

Price vs 52wHigh85%7

1 year return+69%10

Long term

3 year return+459%10

5 year return-20%3

Risk Shield

Price Risk

Beta1.13

Volatility68%2

Free Cash Flow

Free Cash Flow Margin-8%2

Free Cash Flow Yield-0.6%2

Quality

ROCE-8%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

ADPTAdaptive Biotechnologies

Revenue FY25$277M

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+14%8

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+17%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue grew 14%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 17%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 14%/yr over the last 3 years and is set to keep growing around 17%/yr.

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG91 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+8%10

3-month return+30%10

YTD return+62%10

MID & LONG-TERM▾SCORE

% of 52-week high85%7

1-year return+69%10

3-year return+459%10

5-year return-20%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +459% over three years and -20% over five, ahead of 60% of the market.

It's up 69% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+8%), over three months (+30%) and so far this year (+62%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Adaptive Biotechnologies Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ADPTAdaptive Biotechnologies

Revenue FY25$277M

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+14%8

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+17%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue grew 14%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 17%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 14%/yr over the last 3 years and is set to keep growing around 17%/yr.

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG91 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+8%10

3-month return+30%10

YTD return+62%10

MID & LONG-TERM▾SCORE

% of 52-week high85%7

1-year return+69%10

3-year return+459%10

5-year return-20%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +459% over three years and -20% over five, ahead of 60% of the market.

It's up 69% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+8%), over three months (+30%) and so far this year (+62%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Adaptive Biotechnologies Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community